Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

Diabet Med. 2012 May;29(5):690-2. doi: 10.1111/j.1464-5491.2011.03475.x.
No abstract available

Publication types

  • Letter

MeSH terms

  • Automobile Driving*
  • Blood Glucose / drug effects
  • Device Approval / legislation & jurisprudence
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dose-Response Relationship, Drug
  • Exenatide
  • Female
  • Glucagon-Like Peptide 1 / agonists*
  • Glucagon-Like Peptide 1 / analogs & derivatives*
  • Glucagon-Like Peptide 1 / therapeutic use
  • Humans
  • Hypoglycemia / complications
  • Hypoglycemic Agents / therapeutic use*
  • Licensure*
  • Liraglutide
  • Male
  • Middle Aged
  • Peptides / therapeutic use*
  • United Kingdom
  • Venoms / therapeutic use*

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Peptides
  • Venoms
  • Liraglutide
  • Glucagon-Like Peptide 1
  • Exenatide